To date, we have found no studies that show a statistically significant difference in BCSS or OS after a breast cancer diagnosis when BRCA1/2 carriers are compared with matched sporadic controls [15, 18–21, 23, 25, 38–41]. The gene discussed is BRCA1; the disease is breast cancer.